Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 11/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.47 |
| ▸ | CA1 | P00915 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12483510 | 0.88 | CHRNA7 (0.73) | CHRNA7PTGS2PTGS1CA1CA2 | |
| SCHEMBL12483972 | 0.87 | CHRNA7 (0.59) | CHRNA7PTGS2PTGS1CA1CA2 | |
| SCHEMBL12483094 | 0.86 | CHRNA7 (0.56) | CHRNA7PTGS2PTGS1CA1CA2 | |
| SCHEMBL12483300 | 0.86 | CHRNA7 (0.62) | CHRNA7PTGS2PTGS1CA1CA2 | |
| SCHEMBL12483507 | 0.83 | CHRNA7 (0.77) | CHRNA7PTGS2PTGS1CA1CA2 | |
| SCHEMBL12483265 | 0.83 | CHRNA7 (0.59) | CHRNA7PTGS2PTGS1CA1CA2 | |
| SCHEMBL12483894 | 0.81 | CHRNA7 (0.60) | CHRNA7PTGS2PTGS1CA1CA2 | |
| SCHEMBL12482964 | 0.81 | CHRNA7 (0.62) | CHRNA7PTGS2PTGS1CA1CA2 | |
| SCHEMBL12483956 | 0.80 | CHRNA7 (0.59) | CHRNA7PTGS2PTGS1CA2 | |
| SCHEMBL12483436 | 0.79 | CHRNA7 (0.60) | CHRNA7PTGS2PTGS1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2678327-B9 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LTD (IN) | 2016-12-28 | — | — | EP | disclosed |
| EP-2678327-B1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LTD (IN) | 2016-08-17 | — | — | EP | disclosed |
| US-9393247-B2 | Heteroaryl derivatives as alpha7 nAChR modulators | LUPIN LIMITED (IN) | 2016-07-19 | — | — | US | disclosed |
| US-20150231143-A1 | Heteroaryl Derivatives as Alpha7 NACHR Modulators | LUPIN LIMITED (IN) | 2015-08-20 | — | — | US | disclosed |
| US-9072731-B2 | Heteroaryl derivatives as alpha7 nAChR modulators | LUPIN LIMITED (IN) | 2015-07-07 | — | — | US | disclosed |
| EP-2678327-A1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | Lupin Limited (IN) | 2014-01-01 | — | — | EP | disclosed |
| US-20130331387-A1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LIMITED (IN) | 2013-12-12 | — | — | US | disclosed |
| WO-2012114285-A9 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LIMITED (IN) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012114285-A1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LIMITED (IN) | 2012-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331387-A1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | CHRNA7, CHRM1, CHRM2 | CHRNA7 1/4885PTGS2 4837/4885PTGS1 4725/4885 |
| US-20150231143-A1 | Heteroaryl Derivatives as Alpha7 NACHR Modulators | CHRNA7, CHRM1, CHRM2 | CHRNA7 1/4885PTGS2 4832/4885PTGS1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.